Kinase inhibitor
Phase 2Small molecule
Kinase inhibitor is one of 68 small molecule programs targeting Toxicity. It is currently in Phase 2.
2
Indications
2
Total Trials
1
Active Trials
67
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
61 competitors in Toxicity
#DrugCompanyPhaseTrials
1Norvir
AbbVieApproved
Aldactone
PfizerApproved
Oncovin
Eli LillyApproved
Zyvox
PfizerApproved
Lipitor
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Merrem
BB. Braun Medical Inc.
Approved
Prezista
WWim Janssens
Approved
Atropen
FFresenius Kabi Taiwan Ltd.
Approved
Jardiance
Boehringer IngelheimApproved
Ativan
BBausch Health Americas, Inc.
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Kinase inhibitor. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- IImmunocore Ltd